Metastat: Testing for Metastatic Cancer

Predict the risk of cancer metastasis

Metastat is an advanced diagnostic test that investigates the proteins and genes associated with the metastatic spread of cancer. By analyzing circulating tumor cells (CTCs) from the patient’s blood sample, the cancer blood test can help determine whether the cells have a likely potential to metastasize (spread to another organ) or if a secondary cancerous tumor is likely to develop, and where in the body it may occur. 

This information enables clinicians to personalize treatment plans and take proactive measures against metastatic disease by monitoring and adjusting treatment efforts accordingly. 

How does the Metastat test work?

The Metastat test analyzes Circulating Tumor Cells (CTCs), which are shed from the patient’s primary tumor. When a malignant tumor has metastatic potential, it expresses distinct genes and proteins that correspond to the organs it is most likely to spread to. 

Using advanced molecular techniques, Metastat from RGCC measures the levels of specific marker genes and proteins in the blood. These biomarkers reveal whether the tumor has characteristics associated with metastasis and help identify the organs most at risk. 

The results are then compared with baseline data or control samples, providing clinicians with a precise and personalized overview of the cancer’s metastatic profile. 

Who should get the Metastat test?

Metastat is suitable for patients with a confirmed cancer diagnosis. It is especially useful for those who want to assess the risk of cancer spread and potential metastasis.  

By revealing early indicators of metastatic cancer potential, Metastat empowers physicians and patients to make timely, informed decisions that can improve treatment outcomes and long-term prognosis.